Torrent Investments, a key promoter of Torrent Pharmaceuticals, reduced its stake in the company by 2.9% on Wednesday. This transaction, conducted through open market sales, amounted to Rs 3,086 crore. According to BSE bulk deal data, Torrent Investments Pvt Ltd sold 99.44 lakh shares, representing a 2.94% stake in the pharmaceutical firm.

The shares were sold within a price range of Rs 3,103.07 to Rs 3,104.40 each, resulting in a total transaction value of Rs 3,086.37 crore. Following this sale, the promoters’ collective ownership in Torrent Pharmaceuticals decreased from 71.25% to 68.31%. However, the identities of the buyers remain undisclosed on the BSE.

Financial Performance and Market Reaction

Last week, Torrent Pharmaceuticals announced a 17% increase in its consolidated profit after tax for the September quarter, reaching Rs 453 crore. This growth was primarily driven by strong domestic sales. In the same quarter of the previous fiscal year, the company had reported a profit after tax of Rs 386 crore.

During this period under review, Torrent Pharmaceuticals’ revenues rose to Rs 2,889 crore compared to Rs 2,660 crore in the corresponding period last year. The company attributed its revenue growth to a 13% increase in India revenues, which was led by strong performance in key therapeutic areas.

On Wednesday, shares of Torrent Pharmaceuticals experienced a decline of 2.30%, closing at Rs 3,137.15 per share on the BSE.

This recent financial performance highlights Torrent Pharmaceuticals’ ability to maintain growth despite changes in promoter shareholding. The company’s focus on key therapies has contributed significantly to its revenue increase.